Zhong Cheng, Li Yirun, Yang Jing, Jin Shengxi, Chen Guoqiao, Li Duguang, Fan Xiaoxiao, Lin Hui
Department of General Surgery, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
Biomedical Research Center, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
Front Oncol. 2021 Mar 29;11:589680. doi: 10.3389/fonc.2021.589680. eCollection 2021.
Although many approaches have been used to treat hepatocellular carcinoma (HCC), the clinical benefits remain limited, particularly for late stage HCC. In recent years, studies have focused on immunotherapy for HCC. Immunotherapies have shown promising clinical outcomes in several types of cancers and potential therapeutic effects for advanced HCC. In this review, we summarize the immune tolerance and immunotherapeutic strategies for HCC as well as the main challenges of current therapeutic approaches. We also present alternative strategies for overcoming these limitations.
尽管已经采用了许多方法来治疗肝细胞癌（HCC），但临床益处仍然有限，尤其是对于晚期HCC。近年来，研究集中在HCC的免疫治疗上。免疫疗法在几种癌症类型中已显示出有前景的临床结果以及对晚期HCC的潜在治疗效果。在本综述中，我们总结了HCC的免疫耐受和免疫治疗策略以及当前治疗方法的主要挑战。我们还提出了克服这些局限性的替代策略。
